Immunotherapy advances最新文献

筛选
英文 中文
TIM-3: a tumor-associated antigen beyond checkpoint inhibition? TIM-3:一种超越检查点抑制的肿瘤相关抗原?
IF 4.1
Immunotherapy advances Pub Date : 2022-10-21 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac021
Stefan Barth, Krupa Naran
{"title":"TIM-3: a tumor-associated antigen beyond checkpoint inhibition?","authors":"Stefan Barth, Krupa Naran","doi":"10.1093/immadv/ltac021","DOIUrl":"10.1093/immadv/ltac021","url":null,"abstract":"<p><p>Immune checkpoint inhibitors are one of the most remarkable immunomodulatory therapies of current times. Sabatolimab is a high-affinity, humanized anti-TIM-3 monoclonal antibody currently in development for patients with myeloproliferative disorders, including acute myeloid leukemia and myelodysplastic syndromes. By targeting TIM-3, a receptor expressed on various immune effector cells as well as myeloid cells, multiple mechanisms of action that are distinct from canonical immune checkpoint inhibitors are in play - (i) blockade of TIM-3 and its ligands PtdSer/galectin-9, (ii) modulation of leukemic cell self-renewal as well as (iii) antibody-dependent phagocytosis of TIM-3-expressing leukemic cells. Novel immunotherapies such as sabatolimab which enhance the antitumor immune response on converging fronts represent the promise of a continuously replenished armoury for the treatment of cancer.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/41/ltac021.PMC9669666.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40698744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors. 免疫检查点抑制剂对银屑病逆亚型患病率的影响
Immunotherapy advances Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac016
Abdulhadi Jfri, Bonnie Leung, Jordan T Said, Yevgeniy Semenov, Nicole R LeBoeuf
{"title":"Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.","authors":"Abdulhadi Jfri,&nbsp;Bonnie Leung,&nbsp;Jordan T Said,&nbsp;Yevgeniy Semenov,&nbsp;Nicole R LeBoeuf","doi":"10.1093/immadv/ltac016","DOIUrl":"https://doi.org/10.1093/immadv/ltac016","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both <i>de novo</i> and flares, may occur. Evidence is lacking on inverse psoriasis subtype.</p><p><strong>Methods: </strong>A retrospective study was conducted at Dana-Farber Cancer Institute/Mass General Brigham through February 2020 using databases. Confirmed inverse psoriasis cases pre-/post-ICI initiation either independently or in conjunction with other psoriasis subtypes were included. Known psoriasis cases without flare post-ICI were excluded.</p><p><strong>Results: </strong>A total of 262 (3%) individuals with any ICI-mediated psoriasiform cutaneous irAE were identified out of the 8683 DFCI ICI-treated patients. Of these, 13 (5% of psoriasis patients) had inverse psoriasis (mean age 68.7 years; 7/13 male sex). Median (range) time from ICI initiation to inverse psoriasis development or flare was 7 (4-12) and 3.5 (2-6) weeks, respectively. Pruritus occurred in 12/13 (92.30%) cases. 11 (85%) had inguinal involvement; other sites included gluteal cleft (6; 46%), inframammary (3; 23%), perianal (2; 15%), axilla (2; 15%), umbilicus (2; 15%), and infra-abdominal folds (1; 8%). Most (9/13) individuals had more than one site involved. The Common Terminology Criteria for Adverse Events severity was 1 in 10 (76.92%) individuals and 2 in 3 (15.38%) individuals. Six (46.15%) patients were treated initially by oncology with topical (nystatin, econazole, or clotrimazole) or systemic antifungals (fluconazole) for median (range) of 3.5 (1-7) months without improvement, for presumed candida intertrigo.</p><p><strong>Conclusion: </strong>Patients on ICI may develop inverse psoriasis, which may be initially confused for fungal intertrigo. Delayed diagnosis can prolong symptoms, while patients are treated ineffectively with topical/systemic antifungals for presumed candida infection. Oncologist and dermatologist awareness is important to improve diagnosis of ICI-mediated inverse psoriasis, its management and affected patients' quality of life.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/68/ltac016.PMC9525015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33489056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. 口服抗原可以减少或加剧炎症性关节炎动物模型的病理取决于给药的时间。
Immunotherapy advances Pub Date : 2022-09-13 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac020
Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer, Paul Garside
{"title":"Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration.","authors":"Gavin R Meehan,&nbsp;Hannah E Scales,&nbsp;Iain B McInnes,&nbsp;James M Brewer,&nbsp;Paul Garside","doi":"10.1093/immadv/ltac020","DOIUrl":"https://doi.org/10.1093/immadv/ltac020","url":null,"abstract":"<p><p>Currently, treatments for rheumatoid arthritis (RA) are focussed on management of disease symptoms rather than addressing the cause of disease, which could lead to remission and cure. Central to disease development is the induction of autoimmunity through a breach of self-tolerance. Developing approaches to re-establish antigen specific tolerance is therefore an important emerging area of RA research. A crucial step in this research is to employ appropriate animal models to test prospective antigen specific immunotherapies. In this short communication, we evaluate our previously developed model of antigen specific inflammatory arthritis in which ovalbumin-specific T cell receptor transgenic T cells drive breach of tolerance to endogenous antigens to determine the impact that the timing of therapy administration has upon disease progression. Using antigen feeding to induce tolerance we demonstrate that administration prior to articular challenge results in a reduced disease score as evidenced by pathology and serum antibody responses. By contrast, feeding antigen after initiation of disease had the opposite effect and resulted in the exacerbation of pathology. These preliminary data suggest that the timing of antigen administration may be key to the success of tolerogenic immunotherapies. This has important implications for the timing of potential tolerogenic therapies in patients.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40648497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
De-risking clinical trial failure through mechanistic simulation. 通过机制模拟降低临床试验失败的风险。
Immunotherapy advances Pub Date : 2022-08-23 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac017
Liam V Brown, Jonathan Wagg, Rachel Darley, Andy van Hateren, Tim Elliott, Eamonn A Gaffney, Mark C Coles
{"title":"De-risking clinical trial failure through mechanistic simulation.","authors":"Liam V Brown,&nbsp;Jonathan Wagg,&nbsp;Rachel Darley,&nbsp;Andy van Hateren,&nbsp;Tim Elliott,&nbsp;Eamonn A Gaffney,&nbsp;Mark C Coles","doi":"10.1093/immadv/ltac017","DOIUrl":"https://doi.org/10.1093/immadv/ltac017","url":null,"abstract":"<p><p>Drug development typically comprises a combination of pre-clinical experimentation, clinical trials, and statistical data-driven analyses. Therapeutic failure in late-stage clinical development costs the pharmaceutical industry billions of USD per year. Clinical trial simulation represents a key derisking strategy and combining them with mechanistic models allows one to test hypotheses for mechanisms of failure and to improve trial designs. This is illustrated with a T-cell activation model, used to simulate the clinical trials of IMA901, a short-peptide cancer vaccine. Simulation results were consistent with observed outcomes and predicted that responses are limited by peptide off-rates, peptide competition for dendritic cell (DC) binding, and DC migration times. These insights were used to hypothesise alternate trial designs predicted to improve efficacy outcomes. This framework illustrates how mechanistic models can complement clinical, experimental, and data-driven studies to understand, test, and improve trial designs, and how results may differ between humans and mice.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Correction. 修正。
Immunotherapy advances Pub Date : 2022-08-11 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac018
{"title":"Correction.","authors":"","doi":"10.1093/immadv/ltac018","DOIUrl":"https://doi.org/10.1093/immadv/ltac018","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/immadv/ltaa002.][This corrects the article DOI: 10.1093/immadv/ltab010.][This corrects the article DOI: 10.1093/immadv/ltaa007.].</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40709780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. 肥胖和脂肪组织对t细胞反应和癌症免疫检查点阻断治疗的影响。
Immunotherapy advances Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac015
Gabriel Pasquarelli-do-Nascimento, Sabrina Azevedo Machado, Juliana Maria Andrade de Carvalho, Kelly Grace Magalhães
{"title":"Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy.","authors":"Gabriel Pasquarelli-do-Nascimento,&nbsp;Sabrina Azevedo Machado,&nbsp;Juliana Maria Andrade de Carvalho,&nbsp;Kelly Grace Magalhães","doi":"10.1093/immadv/ltac015","DOIUrl":"https://doi.org/10.1093/immadv/ltac015","url":null,"abstract":"<p><p>Many different types of cancer are now well known to have increased occurrence or severity in individuals with obesity. The influence of obesity on cancer and the immune cells in the tumor microenvironment has been thought to be a pleiotropic effect. As key endocrine and immune organs, the highly plastic adipose tissues play crucial roles in obesity pathophysiology, as they show alterations according to environmental cues. Adipose tissues of lean subjects present mostly anti-inflammatory cells that are crucial in tissue remodeling, favoring uncoupling protein 1 expression and non-shivering thermogenesis. Oppositely, obese adipose tissues display massive proinflammatory immune cell infiltration, dying adipocytes, and enhanced crown-like structure formation. In this review, we discuss how obesity can lead to derangements and dysfunctions in antitumor CD8+ T lymphocytes dysfunction. Moreover, we explain how obesity can affect the efficiency of cancer immunotherapy, depicting the mechanisms involved in this process. Cancer immunotherapy management includes monoclonal antibodies targeting the immune checkpoint blockade. Exhausted CD8+ T lymphocytes show elevated programmed cell death-1 (PD-1) expression and highly glycolytic tumors tend to show a good response to anti-PD-1/PD-L1 immunotherapy. Although obesity is a risk factor for the development of several neoplasms and is linked with increased tumor growth and aggressiveness, obesity is also related to improved response to cancer immunotherapy, a phenomenon called the obesity paradox. However, patients affected by obesity present higher incidences of adverse events related to this therapy. These limitations highlight the necessity of a deeper investigation of factors that influence the obesity paradox to improve the application of these therapies.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33443195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Corrigendum to: 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. 胰岛素后100年:免疫疗法作为1型糖尿病的下一个前沿。
Immunotherapy advances Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac013
{"title":"Corrigendum to: 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.","authors":"","doi":"10.1093/immadv/ltac013","DOIUrl":"https://doi.org/10.1093/immadv/ltac013","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/immadv/ltab024.].</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adrenergic signaling regulation of macrophage function: do we understand it yet? 巨噬细胞功能的肾上腺素能信号调节:我们还了解吗?
Immunotherapy advances Pub Date : 2022-06-01 DOI: 10.1093/immadv/ltac010
B. M. Freire, F. M. de Melo, A. Basso
{"title":"Adrenergic signaling regulation of macrophage function: do we understand it yet?","authors":"B. M. Freire, F. M. de Melo, A. Basso","doi":"10.1093/immadv/ltac010","DOIUrl":"https://doi.org/10.1093/immadv/ltac010","url":null,"abstract":"Abstract Macrophages are immune cells that are widespread throughout the body and critical for maintaining tissue homeostasis. Their remarkable plasticity allows them to acquire different phenotypes, becoming able either to fight infection (M1-like, classically activated macrophages) or to promote tissue remodeling and repair (M2-like, alternatively activated macrophages). These phenotypes are induced by different cues present in the microenvironment. Among the factors that might regulate macrophage activation are mediators produced by different branches of the nervous system. The regulation exerted by the sympathetic nervous system (SNS) on macrophages (and the immune system in general) is becoming a subject of increasing interest, indeed a great number of articles have been published lately. Catecholamines (noradrenaline and adrenaline) activate α and β adrenergic receptors expressed by macrophages and shape the effector functions of these cells in contexts as diverse as the small intestine, the lung, or the adipose tissue. Activation of different subsets of receptors seems to produce antagonistic effects, with α adrenergic receptors generally associated with pro-inflammatory functions and β adrenergic receptors (particularly β2) related to the resolution of inflammation and tissue remodeling. However, exceptions to this paradigm have been reported, and the factors contributing to these apparently contradictory observations are still far from being completely understood. Additionally, macrophages per se seem to be sources of catecholamines, which is also a subject of some debate. In this review, we discuss how activation of adrenergic receptors modulates macrophage effector functions and its implications for inflammatory responses and tissue homeostasis.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44712837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Current and future perspectives of chimeric antigen receptors against glioblastoma 胶质母细胞瘤嵌合抗原受体的研究现状与展望
Immunotherapy advances Pub Date : 2022-06-01 DOI: 10.1093/immadv/ltac014
Josephine Zhang, Jesús A. Siller-Farfán
{"title":"Current and future perspectives of chimeric antigen receptors against glioblastoma","authors":"Josephine Zhang, Jesús A. Siller-Farfán","doi":"10.1093/immadv/ltac014","DOIUrl":"https://doi.org/10.1093/immadv/ltac014","url":null,"abstract":"Abstract Glioblastoma multiforme (GBM) is the most malignant form of cancer in the central nervous system; even with treatment, it has a 5-year survival rate of 7.2%. The adoptive cell transfer (ACT) of T cells expressing chimeric antigen receptors (CARs) has shown a remarkable success against hematological malignancies, namely leukemia and multiple myeloma. However, CAR T cell therapy against solid tumors, and more specifically GBM, is still riddled with challenges preventing its widespread adoption. Here, we first establish the obstacles in ACT against GBM, including on-target/off-tumor toxicity, antigen modulation, tumor heterogeneity, and the immunosuppressive tumor microenvironment. We then present recent preclinical and clinical studies targeting well-characterized GBM antigens, which include the interleukin-13 receptor α2 and the epidermal growth factor receptor. Afterward, we turn our attention to alternative targets in GBM, including less-explored antigens such as B7-H3 (CD276), carbonic anhydrase IX, and the GD2 ganglioside. We also discuss additional target ligands, namely CD70, and natural killer group 2 member D ligands. Finally, we present the possibilities afforded by novel CAR architectures. In particular, we examine the use of armored CARs to improve the survival and proliferation of CAR T cells. We conclude by discussing the advantages of tandem and synNotch CARs when targeting multiple GBM antigens.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49654647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy. 靶异构体是嵌合抗原受体细胞治疗中被忽视的挑战和机遇。
Immunotherapy advances Pub Date : 2022-04-20 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac009
Mike Bogetofte Barnkob, Kristoffer Vitting-Seerup, Lars Rønn Olsen
{"title":"Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy.","authors":"Mike Bogetofte Barnkob,&nbsp;Kristoffer Vitting-Seerup,&nbsp;Lars Rønn Olsen","doi":"10.1093/immadv/ltac009","DOIUrl":"https://doi.org/10.1093/immadv/ltac009","url":null,"abstract":"<p><p>The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/1b/ltac009.PMC9327123.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40666628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信